Holen Sie sich die Stockscreener-App
88.86
0.42%
0.37
Handel nachbörslich:
86.50
-2.36
-2.66%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$88.49
Offen:
$88.43
24-Stunden-Volumen:
5.55M
Relative Volume:
0.81
Marktkapitalisierung:
$113.49B
Einnahmen:
$33.20B
Nettoeinkommen (Verlust:
$4.26B
KGV:
27.01
EPS:
3.29
Netto-Cashflow:
$5.47B
1W Leistung:
+0.71%
1M Leistung:
-3.43%
6M Leistung:
-0.29%
1J Leistung:
+4.30%
1-Tages-Spanne:
$87.46
$88.99
1-Wochen-Bereich:
$86.92
$90.31
52-Wochen-Spanne:
$75.96
$96.25
Medtronic Plc Stock (MDT) Company Profile
Firmenname
Medtronic Plc
Sektor
Branche
Telefon
01135314381700
Adresse
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Vergleichen Sie MDT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
ABT
Abbott Laboratories
|
131.93 | 228.81B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-10-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-08-21 | Bestätigt | Oppenheimer | Perform |
| 2024-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2024-08-14 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Sell |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-29 | Herabstufung | UBS | Buy → Sell |
| 2023-01-09 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-11-23 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-23 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-08-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-06-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-27 | Herabstufung | Needham | Buy → Hold |
| 2022-04-13 | Herabstufung | Truist | Buy → Hold |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-16 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-10 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-12-15 | Hochstufung | Goldman | Sell → Neutral |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-10-08 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-10-08 | Hochstufung | Stifel | Hold → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-05-14 | Herabstufung | DZ Bank | Buy → Hold |
| 2020-03-30 | Herabstufung | Needham | Strong Buy → Buy |
| 2020-03-25 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Sell |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-02 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-06-05 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-02-04 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-08-27 | Bestätigt | Argus | Buy |
Alle ansehen
Medtronic Plc Aktie (MDT) Neueste Nachrichten
Medtronic (MDT) Advances But Underperforms Market: Key Facts - Nasdaq
Former Medtronic CEO Criticizes RFK Jr.'s HHS Leadership - Medical Device and Diagnostic industry
Medtronic, Recor commence hostilities over RDN patents - BioWorld MedTech
3 takeaways from ACC 2025 - MedTech Dive
Evercore ISI Adjusts Medtronic Price Target to $105 From $104, Maintains Outperform Rating - MarketScreener
Boston Scientific’s Farapulse Triumphs Over Medtronic’s Artic Front in Atrial Fibrillation Trial - Medical Device and Diagnostic industry
The Zacks Analyst Blog Highlights Mastercard, Medtronic, HCA Healthcare and United Homes - Nasdaq
Medtronic plc (NYSE:MDT) Stake Boosted by Geode Capital Management LLC - MarketBeat
2 Value Stocks I'm Buying Right Now - The Motley Fool
Medtronic Breaks Out Strong TAVR Data at ACC - Medical Device and Diagnostic industry
Medtronic (NYSE:MDT) TAVR System Shows Strong Five-Year Performance Despite 3% Price Dip - Yahoo
Top Stock Reports for Mastercard, Medtronic & HCA Healthcare - Nasdaq
Stifel maintains Hold on Medtronic stock, sets $87 target By Investing.com - Investing.com UK
Medtronic plc (NYSE:MDT) Shares Sold by Meeder Asset Management Inc. - MarketBeat
Medtronic Aortic Valve Replacement Device Shows Improvements Over Surgery in Heart Patients - MarketScreener
Medtronic plc (MDT): Among the Best Dividend Aristocrat Stocks with Over 3% Yield - Yahoo Finance
5-Year Clinical Data: Medtronic TAVR Outperforms Traditional Surgery with Better Heart Outcomes - Stock Titan
Prediction: Buying Medtronic Today Will Set You Up for Life - The Motley Fool
Fed. Circ. Revives Recor's PTAB Challenge To Medtronic IP - Law360
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Medtronic shares trade in green after seven straight days of losses - Seeking Alpha
Otsuka Gets Another Shot Challenging Medtronic Patent's Validity - Bloomberg Law News
Medtronic Stock: A Great Business, But With Low Growth (NYSE:MDT) - Seeking Alpha
Is Medtronic plc (MDT) the Best Consistent Dividend Stock to Buy? - Insider Monkey
Ex-Dividend Reminder: Dick's Sporting Goods, Medtronic and DENTSPLY SIRONA - Nasdaq
Medtronic rolls out Affera PFA system in Sweden with more Nordic countries to follow - Mass Device
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic - Yahoo Finance
Recent U.S. Food and Drug Administration (FDA) approvals - Today's Medical Developments
Investors Heavily Search Medtronic PLC (MDT): Here is What You Need to Know - Yahoo Finance
Looking At Medtronic's Recent Unusual Options Activity - Benzinga
Catheters Market Is Booming Worldwide 2025-2032 | Medtronic, ConvaTec, Inc., Smith Medical, Hollister Incorporated - openPR
Medtronic reports first real-world data on smart insulin pen system - Mass Device
Medtronic’s Evolut trial outcome could shift US TAVR market - Yahoo Finance
Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
An Insider At Medtronic Lowered Their Holding Recently - simplywall.st
Safety Needles Market Detailed In New Research Report 2025 | - openPR
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy - Seeking Alpha
Medtronic, Abbott Block Boston Scientific Heart Valve IP - Law360
“A Lifesaving Opportunity” – Jim Cramer on Medtronic plc (MDT)’s AI-Powered Future - Insider Monkey
Latest device recalls include Medtronic embolization devices - BioWorld Online
Medtronic recalls embolization devices tied to 17 injuries, 4 deaths - MedTech Dive
Tubeless Insulin Pump Market Is Booming Worldwide | Medtronic - openPR
Medtronic recalls embolization device after reported deaths - Mass Device
Medtronic slips after FDA notice on product recall (update) - Seeking Alpha
FDA classifies recall of Medtronic embolization devices as 'most serious' - Reuters.com
FDA Says Medtronic Removes Unused 027 Compatible Pipeline Vantage Embolization Device With Shield Technology - Marketscreener.com
FDA classifies recall of Medtronic embolization devices as 'most serious' -March 18, 2025 at 02:13 pm EDT - Marketscreener.com
Why Medtronic (MDT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Medtronic plc (MDT): Among the Best European Stocks to Buy According to Billionaires - Insider Monkey
Medtronic (MDT) Announces Transition of Principal Accounting Off - GuruFocus.com
Medtronic Announces Leadership Transition in Finance Department - TipRanks
Finanzdaten der Medtronic Plc-Aktie (MDT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):